|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Supplementary Table S3.** Hazard ratios for relapse-free survival estimated using univariate and multivariable proportional hazards regression. SUVmax at cycle 2 (C2) is included as continuous variable in the regression models. | | | | |
|  | **Univariate** | | **Multivariable \*** | |
| **Factor** | **HR (95% CI)** | **P \*\*** | **HR (95% CI)** | **P \*\*** |
|  |  |  |  |  |
| SUVmax C2 | 1.24 (1.07 – 1.43) | 0.003 | 1.30 (1.10 – 1.53) | 0.002 |
| ER or PR positive | 0.67 (0.24 – 1.85) | 0.440 | 0.67 (0.18 – 2.43) | 0.542 |
| Tumor size | 2.20 (0.86 – 5.67) | 0.101 | 1.16 (0.31 – 4.32) | 0.823 |
| Nodal status | 2.88 (0.80 – 10.33) | 0.105 | 3.51 (0.69 – 17.70) | 0.129 |
| Experimental arm | 0.69 (0.24 – 1.93) | 0.476 | 0.44 (0.11 – 1.83) | 0.262 |
| CI: confidence intervals; ER: estrogen receptor; HR: hazard ratio; PR: progesterone receptor; SUVmax: maximum standardized uptake value  \* All variables presented in the table are included into the multivariable model  \*\* Wald test | | | | |